Consistently, a genome-wide MR screen for metabolic dysfunction-associated steatotic liver disease by Ma et al validated GCKR and PCSK9 as tractable drug targets, lending empirical support to this multi-checkpoint strategy.[28]. The gene discussed is PCSK9; the disease is liver disorder.